Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.51 |
| ▸ | BRAF | P15056 | 10/20 | 0.51 |
| ▸ | ABL1 | P00519 | 6/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18775244 | 0.85 | ABL1 (0.52) | EGFRBRAFABL1FGFR1CYP2C9 | |
| SCHEMBL18775253 | 0.84 | ABL1 (0.68) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| SCHEMBL18775248 | 0.83 | RET (0.51) | EGFRBRAFABL1FGFR1CYP2C9 | |
| SCHEMBL18775236 | 0.82 | ABL1 (0.66) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| SCHEMBL12858586 | 0.78 | KIT (0.64) | EGFRBRAFABL1KIT | |
| SCHEMBL17325095 | 0.77 | RET (0.62) | EGFRBRAFABL1FGFR1CYP2C9 | |
| SCHEMBL17325094 | 0.77 | ABL1 (0.64) | EGFRBRAFABL1FGFR1CYP2C9 | |
| SCHEMBL18762351 | 0.77 | ABL1 (0.64) | EGFRBRAFABL1FGFR1CYP2C9 | |
| SCHEMBL17325093 | 0.76 | ABL1 (0.78) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| SCHEMBL17325091 | 0.76 | ABL1 (0.82) | ABL1FGFR1CYP2C9PDGFRACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349588-A1 | 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-12-07 | — | — | US | disclosed |
| US-9765072-B2 | 1H-1,8-naphthyridin-2ones as anti proliferative compounds | NATCO PHARMA LIMITED (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170114057-A1 | 1H-1,8-NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349588-A1 | 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS | ABL1, MKI67, MCL1 | EGFR 424/4885BRAF 272/4885ABL1 1/4885 |
| US-20170114057-A1 | 1H-1,8-NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | ABL1, MKI67, ABL2 | EGFR 464/4885BRAF 244/4885ABL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.